.png)
.png)
Arecor announces launch of new website
Cambridge, UK., 10 January 2018: Arecor Ltd (“the Company”), the leading formulation technology company, focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides to improve the treatment of diabetes and other conditions, is pleased to announce the launch of its new website at:
www.arecor.com
Investors, the press, members of the diabetes community and others seeking to access information on the Company, and regarding its Products, Technology, Management & Board and concerning the Company’s latest news and those forthcoming industry events, which management expects to attend, will now be able to do so through the new website.
*** ENDS ***
For more information, please contact:
Arecor Limited www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426 060
Peckwater PR [email protected]
Tarquin Edwards Tel: +44 (0) 7879 458 364
Notes to Editors
About Arecor
Arecor Ltd is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is currently leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes:
• Stable aqueous glucagon for emergency and artificial pancreas use,
• Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
• Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices.
In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
www.arecor.com
Investors, the press, members of the diabetes community and others seeking to access information on the Company, and regarding its Products, Technology, Management & Board and concerning the Company’s latest news and those forthcoming industry events, which management expects to attend, will now be able to do so through the new website.
*** ENDS ***
For more information, please contact:
Arecor Limited www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426 060
Peckwater PR [email protected]
Tarquin Edwards Tel: +44 (0) 7879 458 364
Notes to Editors
About Arecor
Arecor Ltd is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is currently leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes:
• Stable aqueous glucagon for emergency and artificial pancreas use,
• Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
• Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices.
In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.